Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

Senate Dems Prepare Contingency Plans As Finance Negotiators Grapple For A Deal
"Senate Democrats may decide to pass a U.S. health-care overhaul without Republican support if some opposition lawmakers don"t agree to a plan by mid-September," Senator Charles Schumer[ D-N.Y.] said" according to Bloomberg. Schumer said Sen. Max Baucus, D-Mont., set a self-imposed deadline of Sept. 15 to lead a negotiating team, composed of three Republicans and three Democrats within his Finance Committee, to a bipartisan compromise. Don't forget to buy zoloft online no prescription.

Link Between Obstructive Sleep Apnea And Diabetic Retinopathy
The eyes may be the window into the soul, but they may also contain important medical information. According to new research presented at the American Thoracic Society"s 105th International Conference in San Diego on May 19, patients with diabetes who have retinopathy should also be screened for obstructive sleep apnea (OSA).

generic viagra online


News of the day
Hackers Going After Medical Records
Hackers raided a server at the University of California, Berkeley last fall, stealing everything from Social Security numbers to immunization records in an episode that highlights one danger of moving health information from file cabinets to cyberspace, Forbes reports in a first-person account by one of the 160,000 victims. "Stealing medical data has become more attractive to hackers and identity thieves as banks and individuals have become more sophisticated about protecting credit-building information." One consumer group estimates that as many as 12 percent of digital security breaches target the medical industry.
Nutrition

Versartis Focusing On Extending Half Life Of Drugs For Metabolic And Endocrine Diseases

Versartis, Inc., a new company developing novel biologics with enhanced properties for patients with metabolic diseases, published abstracts for preclinical data on its two product candidates, VRS-859 (exenatide-rPEG) and VRS-808 (glucagon-rPEG), at the American Diabetes Association Scientific Sessions annual meeting beginning today in New Orleans. Versartis, through a unique licensing agreement with Amunix, Inc., uses the proprietary Amunix recombinant PEGylation (rPEG) technology to extend the half life of established biologics.÷  The Versartis compounds in development have the potential for significantly less frequent dosing and fewer side effects than those products currently on the market or in development. "With VRS-859, we have a product candidate that may become a "best in class" GLP-1 analog for the treatment of type 2 diabetes.÷  This compound has similar preclinical efficacy to exenatide in animal models; and the pharmacokinetics in four species support monthly dosing in humans.÷  VRS-859 can also be administered in a small volume with a small gauge needle," said Jeffrey L. Cleland, Ph.D., Founder and Chief Executive Officer of Versartis. "VRS-808 has the potential to prevent nocturnal hypoglycemia in type 1 diabetes, an unmet medical need," Dr. Cleland continued.÷  "VRS-859 and VRS-808 did not have significant toxicology at very high doses in preclinical studies, including a lack of immunogenicity in all studies.÷  We look forward to moving these products rapidly into human clinical trials to benefit diabetes patients." ABSTRACTS Exenatide: 1994-PO -- "An Extended Half-life Exenatide Construct for Weekly Administration in the Treatment of Diabetes Mellitus" The current approved regimen of exenatide for the treatment of type 2 diabetes mellitus requires administration twice a day and is effective in reducing hemoglobin A1c and body weight. Common side effects of this treatment regimen for exenatide include nausea and hypoglycemia, possibly caused by the high peak levels (Cmax) of exenatide after each injection. The ideal dosage form of exenatide would maintain the exenatide blood level in the therapeutic window for at least one week without a high Cmax, which commonly occurs with depot dosage forms. We designed an extended half-life exenatide construct that contains a long unstructured tail of hydrophilic amino acids referred to as rPEG (Exenatide-rPEG; VRS-859). The rPEG tail both increases the serum half-life and provides a slower rate of absorption, thus reducing the peak-trough ratio significantly from the levels seen with twice daily injection of unmodified exenatide. Attachment of rPEG to a model protein (26.9 kDa) increased serum half-life to 75 hrs with a 99% absolute bioavailability following subcutaneous administration in cynomolgus monkeys. A similar half-life extension is expected with exenatide, enabling weekly or every two week dosing in humans. The preclinical efficacy, pharmacokinetics, and immunogenicity of VRS-859 will be presented. The results of these studies will enable rapid progress of the construct into human clinical trials. Glucagon:÷  2001-PO -- "An Extended Half-life Glucagon Construct for the Prevention of Nocturnal Hypoglycemia" Nocturnal hypoglycemia is a common problem for type I diabetics, especially children, often leading to death. Glucagon is typically used to treat acute hypoglycemia, but the short half-life of glucagon ( Versartis


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009